Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: J Neurosci Res. 2015 Aug 31;93(12):1849–1864. doi: 10.1002/jnr.23638

Figure 4. Western blot analysis of glutamatergic biomarkers.

Figure 4

Western blots showing the mean relative optical density of (A) VGLUT-1, (B) VGLUT-2, (C) GLT-1, and (D) EAAC1 protein expression within the DL striatum, NAc and mPFC following treatment with MPTP (n=6–7) or vehicle (n=5–6). (E) Although there were no changes in VGLUT-1 in the NAc, there was a significant 58% and 103% increase of expression compared to the vehicle within the DL striatum and mPFC, respectively, in mice treated MPTP. (F) VGLUT-2 levels significantly decreased 50% compared to the vehicle within the DL striatum of MPTP treated mice. The NAc and mPFC did not show any changes. (G) Expression of GLT-1 significantly decreased 81% compared to the vehicle within the DL striatum of the mice treated with MPTP. Though there weren’t any differences in the mPFC, there was a large increase in expression within the NAc that was trending (p=0.0791). (H) Within the NAc, EAAC1 levels significantly decreased 65% compared to the vehicle in the mice treated with MPTP. The DL striatum and mPFC did not show any differences. Values are means ±S.E.M. *p<0.05.